2. Hirabayashi H, Ebara S, Kinoshita T et al. Clinical outcome and survival after palliative surgery for spinal metastases. Cancer. 2003; 97(2):476–84.1251837210.1002/cncr.11039
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 pt 2):6243S–6249S.10.1158/1078-0432.CCR-06-0931
5. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R et al. Multidisciplinary approach to the treatment of bone metastases: Osteo-oncology center, a new organizational model. Tumori. 2009; 95:291–297.10.1177/030089160909500304
6. Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: A population-based study. Int. Urol. Nephrol. 2018; 50:71–78.
10. Blum R.H., Novetsky D., Shasha D., Fleishman S. The multidisciplinary approach to bone metastases. Oncology. 2003;17:845–857; discussion 862–863, 867.
11. Moriwaki S. Histopathology and statistical analysis of spinal metastases of carcinomas in autopsy cases. Orthop. Surg. Traumatol. 1993; 36:233–241.
12. Vieillard MH, Thureau S. Multidisciplinary meetings dedicated to bone metastases: a historical perspective and rationale. Bull Cancer. 2013; 100:1135–9.
13. Helweg-Larsen S, Henning L. Clinical and autopsy findings in spinal cord compression due to metastatic disease. European Journal of Neurology. 1998; 5.6:587-59213.10.1046/j.1468-1331.1998.560587.x10210894
17. Coleman RE, Brown J, Holen I. Bone metastases. Abeloff’s Clinical Oncology. Content Repository Only!. 2020; 809-830.10.1016/B978-0-323-47674-4.00056-6
19. Guise TA et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research. 2006; 12.20:6213s-6216s.10.1158/1078-0432.CCR-06-100717062703
20. Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Gulley JL. A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget. 2018; 9:102, 37676.
22. Yeoh G, Barton S, Kaestner K. The International Journal of Biochemistry & Cell Biology. Preface. The International Journal of Biochemistry & Cell Biology. 2011; 43.2:172.10.1016/j.biocel.2010.09.00420833257